NASDAQ:GNCA

Genocea Biosciences (GNCA) Stock Forecast, Price & News

$0.0002

0.00 (0.00%)

(As of 09/27/2023 ET)

Compare

Today's Range: $0.0002
▼
$0.0002
50-Day Range: N/A
52-Week Range: $0.0001
▼
$0.0001

Volume: 645 shs
Average Volume: 83,499 shs
Market Capitalization: $11,746.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Genocea Biosciences (NASDAQ:GNCA) Stock

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

GNCA Price History

30 days | 90 days | 365 days | Advanced Chart

GNCA Stock News Headlines

September 21, 2023 | americanbankingnews.com

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.com

January 27, 2023 | seekingalpha.com

GNCAQ Genocea Biosciences, Inc.

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 31, 2022 | thestreet.com

3 Health Care Stocks Under $10 to Trade for Breakouts

August 9, 2022 | uk.finance.yahoo.com

Genocea Biosciences, Inc. (GNCA)

May 27, 2022 | seekingalpha.com

GRPN, GNCA and LAB among mid-day movers

May 25, 2022 | finance.yahoo.com

Genocea Biosciences to shut down

May 24, 2022 | finance.yahoo.com

Genocea Closes Shop, Delists From NASDAQ

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

May 24, 2022 | finance.yahoo.com

Three weeks after layoffs, Genocea shuts down entirely

May 24, 2022 | seekingalpha.com

Genocea stock crashes 64% on winding down of operations, Nasdaq delisting

May 24, 2022 | finance.yahoo.com

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

May 2, 2022 | finance.yahoo.com

Genocea cuts two-thirds of staff, explores a sale

April 29, 2022 | seekingalpha.com

Genocea stock plunges on cutting workforce by 65% and exploring sale or merger alternatives; Stifel cuts PT to $0.16

April 28, 2022 | finance.yahoo.com

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

April 11, 2022 | finance.yahoo.com

Implied Volatility Surging for Genocea (GNCA) Stock Options

April 8, 2022 | uk.investing.com

Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

April 8, 2022 | finance.yahoo.com

Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

April 4, 2022 | finance.yahoo.com

Genocea Biosciences to Host Investor Webinar

March 14, 2022 | finance.yahoo.com

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

March 10, 2022 | seekingalpha.com

Genocea Biosciences GAAP EPS of -$0.19 misses by $0.01

March 10, 2022 | apnews.com

Genocea Biosciences: Q4 Earnings Snapshot

March 10, 2022 | finance.yahoo.com

Genocea Provides Fourth Quarter 2021 Corporate Update

March 9, 2022 | seekingalpha.com

Genocea Biosciences Q4 2021 Earnings Preview

March 9, 2022 | benzinga.com

Genocea Biosciences Earnings Preview

March 8, 2022 | finance.yahoo.com

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

March 3, 2022 | finance.yahoo.com

Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

See More Headlines

Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

GNCA Company Calendar

Last Earnings: 10/27/2021
Today: 9/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GNCA
CUSIP: N/A
CIK: 1457612
Web: www.genocea.com
Phone: (617) 876-8191
Fax: 617-876-8192
Employees: 74
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,200,000.00
Net Margins: N/A
Pretax Margin: -1,946.15%
Return on Equity: -182.88%
Return on Assets: -62.76%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 1.35
Quick Ratio: 1.35

Sales & Book Value

Annual Sales: $1.91 million
Price / Sales: 0.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 58,730,000
Free Float: 57,788,000
Market Cap: $11,746.00
Optionable: Optionable
Beta: 1.61

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. William D. Clark M.B.A. (Age 53)
Pres, CEO & Director
Comp: $837.42k

Dr. Jessica Baker Flechtner Ph.D. (Age 50)
Chief Scientific Officer
Comp: $585.18k

Ms. Diantha Duvall CPA (Age 50)
M.B.A., CFO & Sec.

Key Competitors

View All Competitors

GNCA Stock - Frequently Asked Questions

How have GNCA shares performed in 2023?: Genocea Biosciences' stock was trading at $0.0002 at the start of the year. Since then, GNCA shares have increased by 0.0% and is now trading at $0.0002.
View the best growth stocks for 2023 here.
How were Genocea Biosciences' earnings last quarter?: Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. During the same quarter in the previous year, the firm posted ($0.26) EPS.
What is William Clark's approval rating as Genocea Biosciences' CEO?: 5 employees have rated Genocea Biosciences Chief Executive Officer William Clark on Glassdoor.com. William Clark has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Genocea Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?: Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How do I buy shares of Genocea Biosciences?: Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Genocea Biosciences' stock price today?: One share of GNCA stock can currently be purchased for approximately $0.00.
How much money does Genocea Biosciences make?: Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $11,746.00 and generates $1.91 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.
How can I contact Genocea Biosciences?: Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192.

This page (NASDAQ:GNCA) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genocea Biosciences (GNCA) Stock Forecast, Price & News

About Genocea Biosciences (NASDAQ:GNCA) Stock

GNCA Price History

GNCA Stock News Headlines

GNCA Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GNCA Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info